ASX Announcements
Memphasys is committed to providing shareholders with complete, up-to-the-minute information about the Company. Contact, stock, and corporate information can be found in this section of the website and on the Australian Securities Exchange.
31 December 2024 – Memphasys Half Year Report
20 December 2024 – RoXstaTM Update: Bovine Study Commences…
18 December 2024 – FelixTM Clinical Registration Study Completed
12 December 2024 – LOI with Heranova™ for Greater China
5 December 2024 – Order for Felix™ System in UAE
29 November 2024 – Second Supplementary Prospectus
22 November 2024 – CEO Address to Shareholders
22 November 2024 – AGM Voting Results
21 November 2024 – Chair Appointment
18 November 2024 – Felix™ Clinical Trial 95% Complete
15 November 2024 – RoXsta™ Patent & First Paper
5 November 2024 – SPP & Placement Completion
30 October 2024 – Quarterly Activity Report and Appendix 4C
24 October 2024 – Market Update – Trial Nears Completion
22 October 2024 – Appendix 3B
22 October 2024 – SPP Closing Date Extension
18 October 2024 – Supplementary Prospectus Update
18 October 2024 – Three-Year Equine Fertility Study
8 October 2024 – Supplementary Prospectus
25 September 2024 – Notice of General Meeting
23 September 2024 – RoXsta Patent Application
20 September 2024 – TMD – SPP Prospectus
16 September 2024 – Equine application progress
12 September 2024 – A$2.0m capital raising
4 September 2024 – Strategic Equine Fertility Study
31 July 2024 – June 2024 Quarterly Activity Report & 4C
30 June 2024 – Appendix 4E – Preliminary final report
29 July 2024 – +$1M funding & R&D Tax Rebate loan
24 July 2024 – Sales & Product Development Update
19 July 2024 – Animal R&D progress
6 June 2024 – Dr David Ali appointed CEO
30 May 2024 – Animal industry experts appointed
20 May 2024 – Felix™ benefits in Japanese clinical trial
9 May 2024 – Investor Presentation – Updated 20 May: Link – Updated 3 June: Link
29 April 2024 – March 2024 Quarterly Activity Report & 4C
18 March 2024 – FelixTM Sales Orders Accelerate in Japan
25 January 2024 – AI-Port Update
25 January 2024 – Quarterly Activity Report and Appendix 4C
2 January 2024 – Vitrolife distribution expands (Canada & NZ)